ORUKA THERAPEUTICS INC(ORKA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORKA ORUKA THERAPEUTICS INC

Market Closed 10-09 16:00:00 EDT

82.11

+4.83

+6.25%

盘后82.11

+0.000.00%

19:56 EDT

High82.24	Low77.00	Vol1.21M
Open77.24	D1 Closing77.28	Amplitude6.78%
Mkt Cap5.44B	Tradable Cap4.67B	Total Shares66.21M
T/O98.03M	T/O Rate2.12%	Tradable Shares56.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORKA","market":"US","secType":"STK","nameCN":"ORUKA THERAPEUTICS INC","latestPrice":82.11,"timestamp":1791576000000,"preClose":77.28,"halted":0,"volume":1206683,"hourTrading":{"tag":"盘后","latestPrice":82.11,"preClose":82.11,"latestTime":"19:56 EDT","volume":5977,"amount":490772.91,"timestamp":1791590189270,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06249999999999998,"floatShares":56883996,"shares":66209699,"eps":-2.024183,"marketStatus":"Market Closed","change":4.83,"latestTime":"10-09 16:00:00 EDT","open":77.24,"high":82.24,"low":77,"amount":98027536.14077,"amplitude":0.067805,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.024183,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":77.28,"preHourTrading":{"tag":"盘前","latestPrice":76.78,"preClose":77.28,"latestTime":"09:27 EDT","volume":1111,"amount":85920.41821,"timestamp":1791552467353,"change":-0.5,"changeRate":-0.00647,"amplitude":0.021998},"postHourTrading":{"tag":"盘后","latestPrice":82.11,"preClose":82.11,"latestTime":"19:56 EDT","volume":5977,"amount":490772.91,"timestamp":1791590189270,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.381094869767983,"impliedVol":1.0142,"impliedVolPercentile":0.5857},"requestUrl":"/m/hq/s/ORKA","defaultTab":"news","newsList":[{"id":"2674586596","title":"ORKA-002 Phase 1 Milestone: What Oruka’s First-in-Human Trial Means for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2674586596","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674586596?lang=en_us&edition=fundamental","pubTime":"2026-10-10 00:30","pubTimestamp":1791563423,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. Oruka Therapeutics, Inc. is running a first human study of it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/orka-002-phase-1-milestone-what-orukas-first-in-human-trial-means-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/orka-002-phase-1-milestone-what-orukas-first-in-human-trial-means-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0320765992.SGD","LU0889565916.HKD","ORKA","LU0109394709.USD","ISBC","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672723974","title":"Oruka Therapeutics (ORKA) Just Gave Investors A Fresh Question","url":"https://stock-news.laohu8.com/highlight/detail?id=2672723974","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672723974?lang=en_us&edition=fundamental","pubTime":"2026-10-03 18:16","pubTimestamp":1791022573,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) has released new Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate to severe plaque psoriasis, providing investors with updated information on efficacy and safety.\nOruka Therapeutics has already had a very strong year, with a year to date share price return of 198.97% and a 1 year total shareholder return of 327.08%. However, the 30 day share price return of 7.76% shows some cooling in near term momentum, even as the stock trades at US$84.52...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/oruka-therapeutics-orka-just-gave-investors-a-fresh-question","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/oruka-therapeutics-orka-just-gave-investors-a-fresh-question","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","ORKA","LU0889565916.HKD","LU0109394709.USD","BK4139","ISBC","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672744445","title":"Oruka Therapeutics CEO Lawrence Klein Disposes of $2.09 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672744445","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672744445?lang=en_us&edition=fundamental","pubTime":"2026-10-03 07:55","pubTimestamp":1790985331,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics CEO Lawrence Klein disposes of $2.09 million in common sharesOruka Therapeutics CEO Lawrence Otto Klein exercised an employee warrant for 25,000 shares at $7.80 on Oct. 1, 2026.He s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL8d66wn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics CEO Lawrence Klein Disposes of $2.09 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670492787","title":"Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670492787","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670492787?lang=en_us&edition=fundamental","pubTime":"2026-09-25 01:02","pubTimestamp":1790269368,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics'  lead program of long-acting IL-23 in moderate-to-severe psoriasis maintains a \"competitive profile\" after positive week 28 clinical data, UBS said in a Wednesday note.Oruka's ORKA-001 increased its Psoriasis Area and Severity Index-100 score, which represents the complete resolution of psoriasis, to 71% from 64% in week 16. This compares favorably with rival product, AbbVie's  Skyrizi, which rose to 53% from 43% in the same period, UBS analysts said.The safety data was also consistent with prior data, as treatment-emergent adverse events were 36% in the period of week 16 to 28, compared with 51% during week zero to 16. There were also no injection site reactions and no impact of anti-drug antibodies on safety, efficacy and pharmacokinetics, the analysts noted.The analysts said they are confident in the company's multiple additional readouts later in the year to be positive, \"given the de-risking provided by previous datasets\".UBS' rating on the company's stock is b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0511384066.AUD","LU0256863811.USD","LENZ","AGNG","LU1003077747.HKD","PPH","RXL","BK4007","GLAM","LU0985320562.USD","LU0029864427.USD","ABBV","IE00BVYPNW00.USD","LU2237443549.SGD","LU0124676726.USD","IE00BSNM7G36.USD","LU0395794307.EUR","IYH","BK4588","LU0320765646.SGD","SG9999015986.USD","TRUH","LU2129689514.USD","MEDX","IE000F7OJYX1.SGD","FHLC","IXJ","LU1934455863.HKD","SG9999001440.SGD","PJP","VHT","XLV","LU0256863902.USD","LU0289961442.SGD","LU0432979614.USD","LU1093756168.USD","JDOC","BK4585","LU0795875169.SGD","LU0114720955.EUR","LU0211327993.USD","IE000WAW04H5.SGD","ORKA","IE00BN8TJ469.HKD","LU0198837287.USD","BK4550","IE00B19Z3B42.SGD","FTXH","IE00BLSP4239.USD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670492942","title":"ORKA-002 Trial Progress: What Oruka’s New HS Study Means for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2670492942","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670492942?lang=en_us&edition=fundamental","pubTime":"2026-09-25 00:31","pubTimestamp":1790267467,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. The study A Multicenter, Randomized, Double-Blinded, Placebo-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/orka-002-trial-progress-what-orukas-new-hs-study-means-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/orka-002-trial-progress-what-orukas-new-hs-study-means-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","ISBC","BK4097","ORKA","LU0889565916.HKD","LU2065732104.USD","PRGS","BK4139","BK4211","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669464161","title":"Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669464161","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669464161?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:30","pubTimestamp":1790245831,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), Oruka Therapeutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-oruka-therapeutics-orka-and-harmony-biosciences-holdings-hrmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-oruka-therapeutics-orka-and-harmony-biosciences-holdings-hrmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","IE00BFTCPJ56.SGD","LU0128526141.USD","LABU","HCSG","BK4585","BK4139","LU0889565916.HKD","PRAX","IBRN","IE00BJT1NW94.SGD","BK4007","IE0009355771.USD","HRMY","IE00B2B36J28.USD","IE0002141913.USD","IE00B4R5TH58.HKD","BK4137","BK4581","XBI","LU0320765992.SGD","BK4588","IE00BJJMRZ35.SGD","XLV","LU0029874061.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438452","title":"Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438452?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:30","pubTimestamp":1790184615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunovant (IMVT) and Oruka Therapeutics (ORKA) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunovant-imvt-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunovant-imvt-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","IMVT","LU0889565916.HKD","XLV","LABU","HCSG","XBI","BK4585","LU0128526141.USD","LU0320765992.SGD","BK4139","BK4137","BK4588","ORKA","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486848","title":"Oruka Falls After Reporting Mid-Stage Data for Psoriasis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486848","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486848?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:47","pubTimestamp":1790167639,"startTime":"0","endTime":"0","summary":"BUZZ-Oruka falls after reporting mid-stage data for psoriasis drug** Shares of drug developer Oruka TherapeuticsORKA.Ofall 3.8% to $91 premarket** Co says its experimental drug ORKA-001 showed continu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL4N45F0US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LU0234572021.USD","JDOC","LU0965509283.SGD","LU1983299246.USD","GLAM","IE000MB6IJN5.SGD","LU1551013425.SGD","LU0234570918.USD","LU0868494708.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU0058720904.USD","IXJ","IE00BLSP4452.SGD","AGNG","TRUH","LU0029864427.USD","LU2237443465.HKD","PJP","ABBV","IYH","LU1670627923.USD","LU1934455194.USD","RXL","VHT","LU1839511570.USD","LU0203347892.USD","BK4581","LU0320765992.SGD","LU1244550577.SGD","LU1057294990.SGD","LU0170899867.USD","PPH","ORKA","BK4550","LU1093756325.SGD","IE00B4R5TH58.HKD","IE00BBT3K403.USD","IE00B3PB1722.GBP","FTXH","XLV","IE0002141913.USD","LU1236620750.USD","BK4566","LU2089984988.USD","LU1934455863.HKD","LU0545039389.USD","LU0320765646.SGD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669366488","title":"Oruka Therapeutics announces Week 28 results for ORKA-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2669366488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669366488?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:11","pubTimestamp":1790161863,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-announces-week-28-results-for-orka-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-announces-week-28-results-for-orka-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","ORKA","LU0320765992.SGD","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100268","title":"Oruka Says ORKA-001 Hits 71.4% PASI 100 at Week 28 in Everlast-a Psoriasis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100268","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100268?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:05","pubTimestamp":1790161523,"startTime":"0","endTime":"0","summary":"Oruka says ORKA-001 hits 71.4% PASI 100 at Week 28 in EVERLAST-A psoriasis trialOruka Therapeutics reported positive Week 28 results from its ongoing EVERLAST-A Phase 2a trial of ORKA-001 in plaque ps","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL1RdRn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","SG9999014005.SGD","IE00BN0W2V16.EUR","ORKA","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","BCDF","SG9999014013.SGD","LU2210149790.SGD","BK4112","LU0109394709.USD","IE00BN0W2T93.GBP","BK4139","BK4585","LU0320765992.SGD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU0889565916.HKD","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4588","IE00B3QW5Z07.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669310016","title":"Oruka Therapeutics - Orka-001 Maintains Favorable Safety and Tolerability Profile Through Week 28","url":"https://stock-news.laohu8.com/highlight/detail?id=2669310016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669310016?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:02","pubTimestamp":1790161328,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E11X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100174","title":"Oruka Therapeutics - 52-Week Everlast-a Data Expected in December 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100174?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:02","pubTimestamp":1790161328,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E11X:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0889565916.HKD","LU0109394709.USD","ORKA","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100170","title":"Oruka Therapeutics - Two Serious Adverse Events Reported, Neither Deemed Drug Related","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100170?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:02","pubTimestamp":1790161328,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E11X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","ORKA","BK4139","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100150","title":"Oruka Therapeutics Announces Positive Week 28 Data for Orka-001 from the Ongoing Everlast-a Trial Showing Deepening of Responses Without Additional Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100150?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:02","pubTimestamp":1790161328,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E11X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0109394709.USD","BK4139","LU0320765992.SGD","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488170","title":"Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488170","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669488170?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161200,"startTime":"0","endTime":"0","summary":"PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/23/3367325/0/en/oruka-therapeutics-announces-positive-week-28-data-for-orka-001-from-the-ongoing-everlast-a-trial-showing-deepening-of-responses-without-additional-dosing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSA","REZ","LU0109394709.USD","INDS","BK4588","HAUS","LU0889565916.HKD","REAI","BK4084","LU0320765992.SGD","BK4533","ORKA","BK4585","BK4217","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669965193","title":"Oruka Therapeutics General Counsel Paul Quinlan Disposes of USD 931,699.56 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669965193","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669965193?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:57","pubTimestamp":1790024268,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics General Counsel Paul Quinlan disposes of USD 931,699.56 in common sharesOruka Therapeutics General Counsel Paul T Quinlan exercised an employee warrant to buy 10,000 common shares a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL66T3zV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics General Counsel Paul Quinlan Disposes of USD 931,699.56 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","ORKA","BK4139","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666537112","title":"Oruka Therapeutics to Attend Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666537112","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666537112?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:01","pubTimestamp":1788984075,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics to Attend Morgan Stanley Global Healthcare ConferenceOruka Therapeutics will attend the 2026 Morgan Stanley Global Healthcare Conference in New York on Sept. 14-16, 2026.Disclaimer:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL4RFwDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","NDAQ","ORKA","SG9999014021.USD","BK4112","LU0320765992.SGD","IE00BQXX3F31.USD","BK4585","BK4588","SG9999014039.USD","LU0109394709.USD","LU0889565916.HKD","BK4139","BCDF","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664286455","title":"Oruka Therapeutics CEO Lawrence Klein Sells USD 6.85 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664286455","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664286455?lang=en_us&edition=fundamental","pubTime":"2026-09-02 06:35","pubTimestamp":1788302151,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics CEO Lawrence Klein sells USD 6.85 million in common sharesOruka Therapeutics CEO Lawrence Otto Klein sold 74,999 shares on Sep. 1, 2026 at about $91.81.He also acquired 75,000 share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL8qNt7G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics CEO Lawrence Klein Sells USD 6.85 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0889565916.HKD","LU0109394709.USD","ORKA","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794594","title":"Oruka Therapeutics Files Form 3 for Chief Commercial Officer Larry Todd Edwards","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794594","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662794594?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:36","pubTimestamp":1787736989,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics files Form 3 for Chief Commercial Officer Larry Todd EdwardsOruka Therapeutics filed a Form 3 naming Larry Todd Edwards as chief commercial officer.Disclaimer:This news brief was cr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL681D65:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","ORKA","LU0109394709.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662205703","title":"Oruka Therapeutics Names Todd Edwards Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662205703","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662205703?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:01","pubTimestamp":1787601676,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics names Todd Edwards chief commercial officerOruka Therapeutics named Todd Edwards chief commercial officer, effective Aug. 24, 2026.Edwards joins from Arcutis Biotherapeutics, where ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL6VDQwY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","AGNG","IE00B3PB1722.GBP","LU0689626769.HKD","LU1923622614.USD","BK4550","IE00BN0W2W23.USD","LU0456855351.SGD","PPH","LU1496350502.SGD","GLAM","LU2210149790.SGD","XLV","SG9999014021.USD","LU2125909247.SGD","LU2210150020.SGD","VHT","BCDF","FTXH","LU0820561909.HKD","TRUH","IYH","LU1057294990.SGD","LU1291159041.SGD","LU0211327993.USD","LU0395794307.EUR","LU1718418525.SGD","LU0965508806.USD","MEDX","ABBV","FHLC","LU0124676726.USD","IXJ","ORKA","PJP","NDAQ","LU1551013342.USD","ARQT","RXL","JDOC","LU2347655156.SGD","IE00B2B36J28.USD","LU0949170772.SGD","LU2357627491.SGD","LU0738911758.USD","LU1934455277.USD","LU2129689431.USD","LU0098860793.USD","INCY","IDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.orukatx.com","stockEarnings":[{"period":"1week","weight":-0.0285},{"period":"1month","weight":-0.1026},{"period":"3month","weight":-0.0539},{"period":"6month","weight":0.3781},{"period":"1year","weight":2.2137},{"period":"ytd","weight":1.709}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.352941,"avgChangeRate":0.043718},{"month":2,"riseRate":0.388889,"avgChangeRate":-0.070079},{"month":3,"riseRate":0.388889,"avgChangeRate":-0.00265},{"month":4,"riseRate":0.611111,"avgChangeRate":0.112851},{"month":5,"riseRate":0.5,"avgChangeRate":0.08077},{"month":6,"riseRate":0.333333,"avgChangeRate":0.460115},{"month":7,"riseRate":0.555556,"avgChangeRate":0.025043},{"month":8,"riseRate":0.111111,"avgChangeRate":-0.127193},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.060365},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.022677},{"month":11,"riseRate":0.647059,"avgChangeRate":0.007168},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.002826}],"exchange":"NASDAQ","name":"ORUKA THERAPEUTICS INC","nameEN":"ORUKA THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ORUKA THERAPEUTICS INC(ORKA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ORUKA THERAPEUTICS INC(ORKA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ORUKA THERAPEUTICS INC,ORKA,ORUKA THERAPEUTICS INC股票,ORUKA THERAPEUTICS INC股票老虎,ORUKA THERAPEUTICS INC股票老虎国际,ORUKA THERAPEUTICS INC行情,ORUKA THERAPEUTICS INC股票行情,ORUKA THERAPEUTICS INC股价,ORUKA THERAPEUTICS INC股市,ORUKA THERAPEUTICS INC股票价格,ORUKA THERAPEUTICS INC股票交易,ORUKA THERAPEUTICS INC股票购买,ORUKA THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ORUKA THERAPEUTICS INC(ORKA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ORUKA THERAPEUTICS INC(ORKA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction